Public and investor relations for the innovators in healthcare and technology

Since our founding in 1988, Russo Partners has been working side by side with innovators and influencers in the healthcare and technology industries. Our evolution in the biopharma and healthcare technology ecosystem is unparalleled as is our network, and the knowledge we bring to our clients is extensive. We bring passion, a culture of excellence, forward thinking and client focus every day to everything we do.

Potentially dangerous chemical found in popular heartburn pill Zantac
| CBS News

The nation’s three largest pharmacy chains — Walgreens, Rite Aid and CVS — have stopped selling Zantac and its generic alternative. The heartburn drug, used by millions, was pulled after the Food and Drug Administration (FDA) warned this month it may contain a potentially dangerous impurity. But a CBS News investigation reveals that it might not be just an “impurity” — […]

read more
Pharmacies Pull Zantac Over Concern That Contaminant Poses Cancer Risk

Major U.S. pharmacies have pulled Zantac and its generic equivalent off the shelves after concern about a contaminant that poses a small cancer risk. If you take Zantac, or its generic equivalent for heartburn, it’s time to consider other options. In recent days, major drugstore chains have pulled these products from the shelves. The concern […]

read more
A blood test for cancer
| PharmaVOICE

Detecting cancer early is the key to defeating it. Laboratory for Advanced Medicine (LAM) is working to detect cancer in its infancy when treatment options have the best chance to be successful. The company’s platform technology, IvyGene, detects the presence of cancer in blood samples and gives quantifiable data about the disease. LAM’s approach differs […]

read more